114 related articles for article (PubMed ID: 29734047)
21. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
Reck M; van Zandwijk N; Gridelli C; Baliko Z; Rischin D; Allan S; Krzakowski M; Heigener D
J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854
[TBL] [Abstract][Full Text] [Related]
22. A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer.
Lacouture ME; Keefe DM; Sonis S; Jatoi A; Gernhardt D; Wang T; Doherty JP; Giri N; Nadanaciva S; O'Connell J; Sbar E; Piperdi B; Garon EB
Ann Oncol; 2016 Sep; 27(9):1712-8. PubMed ID: 27287210
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Tolerance of Cetuximab Alone or Combined with Chemotherapy in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: An Open Study of 14 Patients.
Dereure O; Missan H; Girard C; Costes V; Guillot B
Dermatology; 2016; 232(6):721-730. PubMed ID: 28384639
[TBL] [Abstract][Full Text] [Related]
24. Targeted next-generation sequencing of 50 cancer-related genes in Japanese patients with oral squamous cell carcinoma.
Nakagaki T; Tamura M; Kobashi K; Omori A; Koyama R; Idogawa M; Ogi K; Hiratsuka H; Tokino T; Sasaki Y
Tumour Biol; 2018 Sep; 40(9):1010428318800180. PubMed ID: 30226113
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
26. Targeted next-generation sequencing of matched localized and metastatic primary high-risk SCCs identifies driver and co-occurring mutations and novel therapeutic targets.
Lobl MB; Clarey D; Higgins S; Sutton A; Hansen L; Wysong A
J Dermatol Sci; 2020 Jul; 99(1):30-43. PubMed ID: 32595073
[TBL] [Abstract][Full Text] [Related]
27. Panitumumab Treatment for Advanced Penile Squamous Cell Carcinoma When Surgery and Chemotherapy Have Failed.
Necchi A; Giannatempo P; Lo Vullo S; Raggi D; Nicolai N; Colecchia M; Perrone F; Mariani L; Salvioni R
Clin Genitourin Cancer; 2016 Jun; 14(3):231-6. PubMed ID: 26362073
[TBL] [Abstract][Full Text] [Related]
28. Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.
Ready N; Karaseva NA; Orlov SV; Luft AV; Popovych O; Holmlund JT; Wood BA; Leopold L
J Thorac Oncol; 2011 Apr; 6(4):781-5. PubMed ID: 21289522
[TBL] [Abstract][Full Text] [Related]
29. Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study.
Huang J; Fan Q; Lu P; Ying J; Ma C; Liu W; Liu Y; Tan F; Sun Y
J Thorac Oncol; 2016 Jun; 11(6):910-7. PubMed ID: 26980473
[TBL] [Abstract][Full Text] [Related]
30. Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China.
Song B; Cui H; Li Y; Cheng C; Yang B; Wang F; Kong P; Li H; Zhang L; Jia Z; Bi Y; Wang J; Zhou Y; Liu J; Wang J; Zhao Z; Zhang Y; Hu X; Shi R; Yang J; Liu H; Yan T; Li Y; Xu E; Qian Y; Xi Y; Guo S; Chen Y; Wang J; Li G; Liang J; Jia J; Chen X; Guo J; Wang T; Zhang Y; Li Q; Wang C; Cheng X; Zhan Q; Cui Y
Oncotarget; 2016 Jan; 7(3):3599-613. PubMed ID: 26528858
[TBL] [Abstract][Full Text] [Related]
31. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
[TBL] [Abstract][Full Text] [Related]
32. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
[TBL] [Abstract][Full Text] [Related]
33. Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer.
Mok T; Lee K; Tang M; Leung L
Future Oncol; 2014 Apr; 10(5):813-22. PubMed ID: 24799062
[TBL] [Abstract][Full Text] [Related]
34. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Brose MS; Cabanillas ME; Cohen EE; Wirth LJ; Riehl T; Yue H; Sherman SI; Sherman EJ
Lancet Oncol; 2016 Sep; 17(9):1272-82. PubMed ID: 27460442
[TBL] [Abstract][Full Text] [Related]
35. Weekly Multi-agent Chemotherapy (CMF-b) for Advanced Non-melanoma Skin Cancer.
Espeli V; Ruegg E; Hottinger AF; Modarressi A; Dietrich PY
Anticancer Res; 2016 May; 36(5):2359-64. PubMed ID: 27127144
[TBL] [Abstract][Full Text] [Related]
36. High-dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma.
de Castro G; Snitcovsky IM; Gebrim EM; Leitão GM; Nadalin W; Ferraz AR; Federico MH
Eur Arch Otorhinolaryngol; 2007 Dec; 264(12):1475-82. PubMed ID: 17643256
[TBL] [Abstract][Full Text] [Related]
37. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Soria JC; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Isla D; Guclu SZ; Morabito A; Min YJ; Ardizzoni A; Gadgeel SM; Wang B; Chand VK; Goss GD;
Lancet Oncol; 2015 Aug; 16(8):897-907. PubMed ID: 26156651
[TBL] [Abstract][Full Text] [Related]
38. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
39. Cetuximab in metastatic squamous cell cancer of the skin: a Swiss case series.
Conen KL; Fischer N; Hofbauer GF; Shafaeddin-Schreve B; Winterhalder R; Rochlitz C; Zippelius A
Dermatology; 2014; 229(2):97-101. PubMed ID: 24923455
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
